AR114354A2 - PYRIMIDINE DERIVATIVES - Google Patents

PYRIMIDINE DERIVATIVES

Info

Publication number
AR114354A2
AR114354A2 ARP190100267A ARP190100267A AR114354A2 AR 114354 A2 AR114354 A2 AR 114354A2 AR P190100267 A ARP190100267 A AR P190100267A AR P190100267 A ARP190100267 A AR P190100267A AR 114354 A2 AR114354 A2 AR 114354A2
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkoxy
alkyl
aryl
Prior art date
Application number
ARP190100267A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR114354A2 publication Critical patent/AR114354A2/en

Links

Abstract

Reivindicación 1: Un compuesto de fórmula (1), en donde cada uno de R⁰, R¹, R² y R³ es independientemente hidrógeno, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₈, aril C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈, haloalquilo C₁₋₈, arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, aril C₅₋₁₀-alcoxi C₁₋₈ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, sulfamoílo no sustituido o sustituido, ciano o nitro; o R⁰ y R¹, R¹ y R², y/o R² y R³ forman, junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; R⁴ es hidrógeno o alquilo C₁₋₈; cada uno de R⁵ y R⁶ independientemente es hidrógeno, alquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, haloalquilo C₁₋₈, alcoxi C₁₋₈, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, ciano, o nitro; y cada uno de R⁷, R⁸, R⁹ y R¹⁰ independientemente es alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₈, arilo C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈, haloalquilo C₁₋₈, arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, arilo C₅₋₁₀-alcoxi C₁₋₈ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, sulfamoílo no sustituido o sustituido, ciano o nitro; en donde R⁷, R⁸ y R⁹ independientemente entre sí también pueden ser hidrógeno; o R⁷ y R⁸, R⁸ y R⁹, y/o R⁹ y R¹⁰ forman junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; A es C o N; y sus sales.Claim 1: A compound of formula (1), wherein each of R⁰, R¹, R² and R³ is independently hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, C₃₋ cycloalkyl ₈-C₁₋₈ alkyl, C₅₋₁₀ aryl-C₁₋₈ alkyl, C₁₋₈ hydroxyalkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, unsubstituted or substituted C₅₋₁₀ aryl , unsubstituted or substituted 5- or 6-membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C alco alkoxy-C₁₋₈ alkoxy, haloalkoxy C₁₋₈, unsubstituted or substituted C₅₋₁₀ aryl-C₁₋₈ alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted C₁₋₈ heterocyclylalkoxy, unsubstituted or substituted amino, C₁₋₈ alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl, C₅₋₁₀ arylsulfonyl, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; or R⁰ and R¹, R¹ and R², and / or R² and R³ form, together with the carbon atoms to which they are attached, a 5- or 6-membered carbocyclic or heterocyclic ring comprising 0, 1, 2, or 3 selected heteroatoms of N, O and S; R⁴ is hydrogen or C₁₋₈ alkyl; each of R⁵ and R⁶ independently is hydrogen, C alqu alkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxy, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, cyano, or nitro; and each of R⁷, R⁸, R⁹ and R cada independently is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl-C alqu alkyl, C₅₋₁₀ aryl-C alqu alkyl ₋₈, C₁₋₈ hydroxyalkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, unsubstituted or substituted C₅₋₁₀ aryl, unsubstituted or substituted 5- or 6-membered heterocyclyl comprising 1 , 2 or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C₁₋₈ alkoxy-C₁₋₈ alkoxy, C₁₋₈ haloalkoxy, C₅₋₁₀ aryl-C₁₋₈ alkoxy no substituted or substituted, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted C₁₋₈ heterocyclylalkoxy, unsubstituted or substituted amino, C₁₋₈ alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl, C₅₋₁₀ arylsulfonyl, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; where R⁷, R⁸ and R⁹ independently of each other can also be hydrogen; or R⁷ and R⁸, R⁸ and R⁹, and / or R⁹ and R¹⁰ form, together with the carbon atoms to which they are attached, a 5- or 6-membered carbocyclic or heterocyclic ring comprising 0, 1, 2, or 3 heteroatoms selected from N, O and S; A is C or N; and its salts.

ARP190100267A 2003-08-15 2019-02-04 PYRIMIDINE DERIVATIVES AR114354A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
AR114354A2 true AR114354A2 (en) 2020-08-26

Family

ID=28052593

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100728A AR107965A2 (en) 2003-08-15 2017-03-23 PIRIMIDINE DERIVATIVES
ARP190100267A AR114354A2 (en) 2003-08-15 2019-02-04 PYRIMIDINE DERIVATIVES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170100728A AR107965A2 (en) 2003-08-15 2017-03-23 PIRIMIDINE DERIVATIVES

Country Status (3)

Country Link
CN (1) CN1832929B (en)
AR (2) AR107965A2 (en)
GB (1) GB0319227D0 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671744C (en) * 2006-12-08 2012-08-28 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2432900A4 (en) * 2009-05-15 2012-11-21 Insight Genetics Inc Methods and compositions relating to fusions of alk for diagnosing and treating cancer
AU2013344049B2 (en) * 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
EP2970205B1 (en) * 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
CN104628657A (en) * 2013-11-06 2015-05-20 韩冰 Class of compounds for treating ischemic brain damage and purpose thereof
CN104926794B (en) * 2014-03-17 2017-12-05 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
CN106008503B (en) * 2015-03-31 2020-09-01 齐鲁制药有限公司 Spirocyclic aryl sulfones as protein kinase inhibitors
CN106146525B (en) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 Three and ring class anaplastic lymphoma kinase inhibitor
CN106187915A (en) * 2015-05-27 2016-12-07 上海翰森生物医药科技有限公司 There is inhibitor of ALK Yu EGFR double activity and its preparation method and application
CN106349224A (en) * 2016-08-03 2017-01-25 山东大学 JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof
CN110092759A (en) * 2018-01-31 2019-08-06 陆柯潮 The chloro- 2,4- pyrimidine derivatives of 5- as anti-tumor drug
CN114716385B (en) * 2022-04-08 2024-03-12 北京师范大学 Compound of targeted focal adhesion kinase, preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
GB0319227D0 (en) 2003-09-17
CN1832929B (en) 2012-11-07
CN1832929A (en) 2006-09-13
AR107965A2 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
AR114354A2 (en) PYRIMIDINE DERIVATIVES
AR045458A1 (en) PIRIMIDINE DERIVATIVES
AR107966A2 (en) INHIBITING PYRIMIDINE AND PYRIDINE DERIVATIVES OF THE QUINASA PROTEIN
AR111279A1 (en) USEFUL HETEROCYCLIC DERIVATIVES AS DUAL INHIBITORS OF ATX / CA
CO6251260A2 (en) BIFENYLL DERIVATIVES CONFORMALLY RESTRICTED FOR USE AS INHIBITORS OF THE HEPATITIS VIRUS C.
CO5700764A2 (en) DIHYDROQUINAZOLINS REPLACED WITH ANTIVIRAL PROPERTIES
CO6270328A2 (en) PIRROLO DERIVATIVES [2,3] PYRIMIDINE AS INHIBITORS OF KINASE PROTEINS B
AR060651A1 (en) DERIVATIVES OF 1,2,4-TRIAZOL AS MODULATORS OF MGLUR5 I, INTERMEDIARIES FOR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PAIN AND GASTROINTESTINAL DISORDERS
CO5640117A2 (en) 2,4-DIAMONOPIRIMIDINE DERIVATIVES
AR070463A1 (en) AMINA AND ETER COMPOUNDS THAT MODULATE THE CB2 RECEIVER
CO4950625A1 (en) NICOTINAMIDE DERIVATIVES
AR046083A1 (en) DERIVATIVES OF 2 PIRIDONA AS INHIBITORS OF THE ELASTASA DE NEUTROFILOS
AR116913A1 (en) APOL1 INHIBITORS AND THEIR USE METHODS
BRPI0519288A2 (en) heterocyclic compounds as ccr2b antagonists
ES2271615T3 (en) N-ARIL-2-OXAZOLIDINONA-5-CARBOXAMIDS AND ITS DERIVATIVES AND ITS USE AS ANTIBACTERIALS.
AR099498A1 (en) TRIAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE
CO5690551A2 (en) TETRAZOL DERIVATIVES AND METHODS FOR TREATMENT WITH THE SAME DISORDERS RELATED TO METABOLISM
AR096846A1 (en) DIHYDROCHINOXALINONES AND MODIFIED DIHYDROPIRIDOPIRAZINONES AS INHIBITORS OF BET PROTEIN
AR060812A1 (en) MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN
AR051325A1 (en) BIARILQUINOLIN-4-ILAMINA SUBSTITUTED ANALOGS
AR110282A1 (en) BICYCLIC AMIDA COMPOUNDS AND USE OF THESE IN THE TREATMENT OF DISEASES MEDIATED BY RIP1
CO5720994A2 (en) PIRROL REPLACED DERIVATIVES
AR060810A1 (en) MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN
AR110498A1 (en) DERIVATIVES OF ISOXAZOLIL Ether AS POSITIVE ALOSTERIC MODULATORS (PAM) OF GABAA RECEPTORS a5
AR066604A1 (en) DERIVATIVES OF ARILAMIDA PIRIMIDONA, MEDICINES THAT CONTAIN THEM AND THERAPEUTIC USES TO PREVENT AND / OR TREAT FUNDAMENTALALLY NEURODEGENERATIVE DISEASES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure